Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
Other causes if liver disease excluded.
Related Questions
Do you utilize temporal artery ultrasound in your practice?
When do you consider Mesna for patients taking oral cyclophosphamide?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
How do you approach the management of patients with moderate to high pre-test probabilty of GCA who are found to have negative findings on temporal artery biopsy?
What would be the preferred treatment option for PMR if patient develops gastric perforation soon after initiation of steroids?
Do you consider immunosuppression in a patient with cocaine-induced midline lesions who is ANCA positive, but has no other evidence of vasculitis?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
Would you stop azathioprine in a patient with ANCA vasculitis who has been in long term remission on azathioprine, but has a new diagnosis of lung cancer requiring initiation of immunotherapy?
How soon after starting treatment would you repeat imaging in patients with Takayasu to monitor response and ensure you have the correct diagnosis?